UEG week virtual 2021

Where is the future in IBD treatment? P19, JAKi, S1P?

Is STRIDE II already history?

How to significantly reduce the arterial vascular risk in IBD treatment (with anti-TNF and thiopurine)

Discontinuation strategies: Data hint towards continuing Infliximab in CD patients with remission

UEG highlights: Vedolizumab in Chronic pouchitis;

Maintenance with Upadacitinib

IL-23: Risankizumab - effective maintenance, long carry over of clinical remission.

What's the right target? JAK1 or JAK3 or TYK2?

STRIDE 2.0 - Treatment goals in IBD: Patient Perspectives, Transmural healing

Single JAK targeting: JAK1 vs. JAK3

Side Effects - Biologicals: News from UEGw

A panoramic view of UEG and IBD from Spain

Do we need H2H trials? We need new endpoints, regaining QoL, there is still more to explore!

Treatment targets: The impact of STRIDE II on our clinical practice. New targets needed!

What do drug levels and antibody levels tell us?

What's the right target? JAK1 or JAK3 or TYK2?

Do we need IL-23 blockade? Are all inhibitors the same?

Targeting S1P: effective, well tolerated, soon to be approved. Affordable?

Review JAK1 Inhibition: great speed of action, execellent maintenance, well tolerated.

Tofacitinib numerically increases Herp Zoster risk however without high severity. More data needed.

IL-23: Risankizumab - effective maintenance, long carry over of clinical remission.

Dose escalation strategies to increase the efficacy of Ustekinumab

S1P targeting: very immediate effficacy and good safety profile

UEG highlights: Vedolizumab in Chronic pouchitis;

Maintenance with Upadacitinib

Upadacitinib with rapid and effective control of symptoms and reduction of inflammation markers

Single JAK targeting: JAK1 vs. JAK3

JAK1 vs. JAK3 - was ist effektiver?

Risankizumab: Effektive Erhaltung mit Langzeiteffekt

UEG highlights: Vedolizumab in Chronic pouchitis;

Maintenance with Upadacitinib

S1P Rezeptor Agonisten mit unmittelbarer Effektivität und guter Verträglichkeit

Dose escalation strategies to increase the efficacy of Ustekinumab

Neue JAK-Therapieoptionen vor der Zulassung. Es wird komplexer!

Immunosuppression and COVID: vaccination is effective, booster required, do not discontinue IMM and/or biologics

Side Effects - Biologicals: News from UEGw

Side Effects - Oral Therapies: News from UEGw

How to significantly reduce the arterial vascular risk in IBD treatment (with anti-TNF and thiopurine)

Safety of Ustekinumab in elderly patients - no increased risk

Protein profiling as efficacy predictor of infliximab treatment

IBD w wieku podeszłym - czy można bezpiecznie stosować ustekinumab?

Comment réduire le risque cardio-vasculaire associé aux MICI

Protein profiling as efficacy predictor of infliximab treatment

Disease Clearance in UC: How can we translate this into clinical practice? The importance of histologic healing.

What ist the most exciting new drug on the horizon? (UEGw and beyond)

Microbiome, nutrition and life style: The effect on disease outcome, consider local dietary options and remember diversity

Is STRIDE II already history?

Disease clearance? Treat to target still correct?

PK SEAVUE Study: high proportion of patients with anti-drug antibodies does not affect efficacy

Do not stop infliximab in patients in complete remission

SEAVUE PK update: Immunogenicity of Ustekinumab vs Adalimumab

Risankizumab: 12 weeks induction in patients wo initial response can recapture >60%

Discontinuation strategies: Data hint towards continuing Infliximab in CD patients with remission

Mieux vaut ne pas arrêter l’infliximab dans la maladie de Crohn

Czy warto kończyć terapię IFX w przypadku głębokiej remisji choroby Crohna?

Ustekinumab e Adalimumab: farmacocinetica e immunogenicità a confronto. Dati dallo studio SEAVUE.

STRIDE 2.0 - Treatment goals in IBD: Patient Perspectives, Transmural healing

JAK inhibitors showing quick response in PRO improvement.

Disease Clearance the future therapeutic goal (endoscopic, histologic and clinical remission)

Therapieziele - STRIDE 2.0: Die Patientenperspektive, endoskopic remission, histologic remission clinical remission

JAK inhibitors e rapidità nel miglioramento dei PROs: i nuovi steroidi?

Therapieziele: Disease Clearance bei der Colitis Ulcerosa

Vedolizumab effective in resistant pouchitis

UEG highlights: Vedolizumab in Chronic pouchitis;

Maintenance with Upadacitinib

New treatment options: IL23 modulators Risankizumab and Guselkumab

Ritlecitinib & Brepocitinib good remission rates and good safety date

New treatment options about to be approved. Treatment choices will become more complex!

Neue Therapieoptionen: IL23 Modulation durch Risankizumab und Giselkumab

Ritlecitinib e Prebocitinib i nuovi arrivati nel mondo dei JAK inibitori

UEG highlights: Vedolizumab in Chronic pouchitis;

Maintenance with Upadacitinib

Where is the future in IBD treatment? P19, JAKi, S1P?

UEG highlights: Vedolizumab in Chronic pouchitis;

Maintenance with Upadacitinib

A panoramic view of UEG and IBD from Spain

No assocation between COVID outcome and IBD therapy

Spanish IBD contributions to UEGW: more and more important

Aportación española a la UEGW en EII: más y mejor

Un visión panorámica de la UEG y la EII desde España

No assocation between COVID outcome and IBD therapy

UEG highlights: Vedolizumab in Chronic pouchitis;

Maintenance with Upadacitinib